# Daridorexant to Prevent Delirium After Heart Surgery

> **NCT06630390** · PHASE2 · COMPLETED · sponsor: **University of Rochester** · enrollment: 11 (actual)

## Conditions studied

- POSTOPERATIVE DELIRIUM
- POSTOPERATIVE COGNITIVE DECLINE

## Interventions

- **DRUG:** Daridorexant 50 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06630390
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-11
- **Primary completion:** 2025-02-16
- **Final completion:** 2025-02-16
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630390, "Daridorexant to Prevent Delirium After Heart Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06630390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*